Media coverage
29
Media coverage
Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Morningstar.com Country/Territory United States Date 13/02/21 URL https://www.morningstar.com/news/globe-newswire/8152587/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet TMC Net Country/Territory United States Date 13/02/21 URL www.tmcnet.com/usubmit/-fda-approves-g1-therapeutics-coselatrade-trilaciclib-first-only-/2021/02/12/9307369.htm Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA™ (trilaciclib): The … Media name/outlet TMC Net Country/Territory United States Date 13/02/21 URL www.tmcnet.com/usubmit/-fda-approves-g1-therapeutics-coselatrade-trilaciclib-first-only-/2021/02/12/9307369.htm Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet BioSpace Country/Territory United States Date 13/02/21 URL https://www.biospace.com/article/releases/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression/?s=74 Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and.. Media name/outlet ADVFN UK Country/Territory United Kingdom Date 13/02/21 URL https://uk.advfn.com/stock-market/NASDAQ/GTHX/share-news/FDA-Approves-G1-Therapeutics-COSELA-trilaciclib/84331214 Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence... Media name/outlet ADVFN UK Country/Territory United Kingdom Date 13/02/21 URL https://uk.advfn.com/stock-market/NASDAQ/GTHX/share-news/FDA-Approves-G1-Therapeutics-COSELA-trilaciclib/84331214 Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA(TM) (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet MicroSmallCap Country/Territory Canada Date 13/02/21 URL https://microsmallcap.com/fda-approves-g1-therapeutics-coselatm-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Yahoo! Canada Country/Territory Canada Date 13/02/21 URL https://ca.sports.yahoo.com/news/fda-approves-g1-therapeutics-cosela-004100120.html Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet StocksNewsFeed.com Country/Territory United States Date 13/02/21 URL https://stocksnewsfeed.com/globenewswire/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression/ Persons William Roberts Title FDA APPROVES G1 THERAPEUTICS' COSELA™ (TRILACICLIB) : The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet MarketScreener.com Country/Territory United States Date 13/02/21 URL https://www.marketscreener.com/quote/stock/G1-THERAPEUTICS-INC-34912629/news/FDA-Approves-G1-Therapeutics-COSELA-trade-trilaciclib-The-First-and-Only-Myeloprotection-Therap-32432062/ Persons William Roberts Title FDA Approves G1 Therapeutics ’ COSELA ™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Stockwatch Country/Territory Canada Date 13/02/21 URL www.stockwatch.com/News/Item?bid=U-z8152587-U:GTHX-20210212&symbol=GTHX®ion=U Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Market Newsdesk Country/Territory United States Date 13/02/21 URL www.marketnewsdesk.com/?p=435373 Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Crwe World Country/Territory United States Date 13/02/21 URL crweworld.com/article/news-provided-by-globenewswire/1883308/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet WVB Country/Territory United States Date 13/02/21 URL wvb.com/news/industry/view/id/9640357 Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Yahoo! Finanzas Country/Territory United States Date 13/02/21 URL https://es-us.finanzas.yahoo.com/news/fda-approves-g1-therapeutics-cosela-004100120.html Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Customer Zone 360.com Country/Territory United States Date 13/02/21 URL www.customerzone360.com/news/2021/02/12/9307369.htm Persons William Roberts Title $GTHX FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet OTC Dynamics Country/Territory Canada Date 13/02/21 URL https://www.otcdynamics.com/gthx-fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression/ Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Biotechgate Country/Territory Switzerland Date 13/02/21 URL www.biotechgate.com/gate/v3/news_details.php?news_id=231373&page_id=?next=1 Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA(TM) (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Chase Country/Territory United States Date 13/02/21 URL https://idc.chase.com/newspublic/story?article=319e8029af012ba5&module=default Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA(TM) (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet TD Ameritrade Country/Territory United States Date 13/02/21 URL https://research.tdameritrade.com/grid/public/markets/news/story.asp?fromPage=results&docKey=100-043u9536 Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Valuespectrum.com Country/Territory United States Date 13/02/21 URL www.valuespectrum.com/corporate_news/556856-fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA(TM) (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet TradingCharts.com Country/Territory United States Date 13/02/21 URL https://futures.tradingcharts.com/news/futures/FDA_Approves_G1_Therapeutics__COSELA_TM___trilaciclib___The_First_and_Only_Myeloprotection_Therapy_to_Decrease_the_Incidence_of_Chemotherapy_Induced_Myelosuppression_380774308.html Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet IT Business Net Country/Territory United States Date 13/02/21 URL www.itbusinessnet.com/2021/02/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression/ Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy ... Media name/outlet Bakersfield.com Country/Territory United States Date 13/02/21 URL https://www.bakersfield.com/ap/news/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy/article_aa4d872a-98a5-56e3-b246-45515bd0a3a1.html Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of ... Media name/outlet EIN Presswire Country/Territory United States Date 13/02/21 URL https://www.einpresswire.com/article/535477007/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet GlobeNewswire Country/Territory United States Date 13/02/21 URL www.globenewswire.com/news-release/2021/02/13/2175184/0/en/FDA-Approves-G1-Therapeutics-COSELA-trilaciclib-The-First-and-Only-Myeloprotection-Therapy-to-Decrease-the-Incidence-of-Chemotherapy-Induced-Myelosuppression.html Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet BizWire Express Country/Territory India Date 13/02/21 URL www.bizwireexpress.com/showstoryGNW.php?storyid=140907 Persons William Roberts Title FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Media name/outlet Forex TV Country/Territory United States Date 13/02/21 URL https://forextv.com/top-news/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression/ Persons William Roberts Title FDA Approves G1 Therapeutics' COSELA(TM) (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy Induced Myelosuppression Media name/outlet Market News Publishing Country/Territory United States Date 12/02/21 Persons William Roberts